WAT : Analysis & Opinions

  1. CECO Receives Bulk Orders Worth $15M - Analyst Blog

    June 26, 2013
    CECO Environmental Corp. announced yesterday winning several new orders worth $15 million from across the globe.
  2. FEI Still A Big Play On The Very Small

    February 11, 2013
    FEI has excellent growth potential, but valuation is a bit steep.
  3. New Analyst Coverage

    October 16, 2012
    New York, May 17th (TradersHuddle.com) - These are the research analyst new ratings before the market open. Crocs (NASDAQ:CROX) ...
  4. Agilent Still A Name Worth Owning

    May 16, 2012
    Agilent looks poised for a EMG rebound.
  5. Forget Nano, FEI Is Real

    April 10, 2012
    Forget the nano hype, FEI is a real company in the analytical technology space.
  6. Neogen Is Almost Cheap

    December 30, 2011
    Neogen has to do more to validate this price.
  7. Renewed Realism May Make Life Tech A Buy

    November 30, 2011
    It may be time to consider Life Tech as a good blue-chip play in the health-care sector.
  8. R&D The Future For Life Sciences Equipment Firms

    September 20, 2011
    Finding new healthcare solutions will be a paramount concern going forward. For investors, the best way to profit from this ...
  9. Illumina Gets Capped And Cut

    August 4, 2011
    Illumina's sky-high valuation takes a beating on lower guidance.
  10. Agilent Overshoots

    May 17, 2011
    Agilent has more than made up for lost time and is emerging as a popular growth company with multiple streams of revenue.
  11. Illumina Lights Up Again

    April 29, 2011
    Illumina is a torrid grower, and growth investors seem to be willing to pay any price.
  12. Thermo Fisher Pays A High Price For Quality

    December 15, 2010
    Thermo Fisher makes a very reasonable purchase but pays a price to do so.
  13. A Fistfull Of Life Sciences

    October 29, 2010
    The life sciences field is showing encouraging growth and mostly reasonable valuations.
  14. Agile Agilent

    August 18, 2010
    Agilent may defy easy categorization, but its quality does not depend on labels.
  15. Teleflex Aims For Less Flux

    May 6, 2009
    Teleflex’s business seems to be in a continual state of flux.
  16. How Much Vigor In Invitrogen?

    October 27, 2008
    Invitrogen is in the right space, but does management have the right plan?
  17. Bidding Frenzy Hits Genetic Testing Stocks

    June 13, 2008
    Genetic testing to assess future disease risk is about to go mainstream. This promted a take-over free-for-all in the sector.
  18. Analyze This (TMO, A, WAT)

    April 13, 2007
    A comparison of three analytical and diagnostic technology companies.
Investing News
  1. Thoughts From The Frontline: Every Central Bank For Itself

    Thoughts from the Frontline: Every Central Bank for Itself
  2. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  3. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  4. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  5. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  6. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
Trading Center